Apnimed secures $192M upsized IPO to launch sleep apnea pill Oxnimbi on July 31, 2026 AD109 APMD Apnimed IPO Nasdaq Oxnimbi Sleep Apnea Syndromes United States Food and Drug Administration upsized +
Apnimed Targets Up to $160M IPO for Sleep Apnea Drug Oxnimbi Launch on July 28, 2026 AD109 APMD Apnimed Approved IPO Oxnimbi Phase 3 trials Sleep Apnea Syndromes Sleep Apnea, Obstructive United States Food and Drug Administration +
Shionogi to Acquire Apnimed's 50% Stake in Sleep Science Joint Venture for $100M Upfront on March 24, 2026 Apnimed Joint Ventures SASS shionogi Sleep Apnea Syndromes +
Apnimed Advances FDA Filing after Second Pivotal Win for Oral Sleep Apnoea Drug on July 24, 2025 AD109 Apnimed aroxybutynin atomoxetine Clinical Trials LunAIRo oral drug Sleep Apnea, Obstructive submission SynAIRgy United States Food and Drug Administration +